Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ELF1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ELF1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ELF1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ELF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ELF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ELF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ELF1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ELF1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ELF1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ELF1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ELF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507791 | Colorectum | MSS | RNA destabilization | 31/3467 | 88/18723 | 1.49e-04 | 2.18e-03 | 31 |
GO:00486381 | Colorectum | MSS | regulation of developmental growth | 84/3467 | 330/18723 | 1.01e-03 | 1.01e-02 | 84 |
GO:00486391 | Colorectum | MSS | positive regulation of developmental growth | 49/3467 | 174/18723 | 1.17e-03 | 1.13e-02 | 49 |
GO:00459272 | Colorectum | MSS | positive regulation of growth | 68/3467 | 259/18723 | 1.24e-03 | 1.19e-02 | 68 |
GO:0017148 | Colorectum | MSS | negative regulation of translation | 64/3467 | 245/18723 | 1.94e-03 | 1.67e-02 | 64 |
GO:0034249 | Colorectum | MSS | negative regulation of cellular amide metabolic process | 70/3467 | 273/18723 | 2.07e-03 | 1.76e-02 | 70 |
GO:0035264 | Colorectum | MSS | multicellular organism growth | 37/3467 | 132/18723 | 4.77e-03 | 3.34e-02 | 37 |
GO:00063761 | Colorectum | MSS | mRNA splice site selection | 17/3467 | 49/18723 | 5.28e-03 | 3.61e-02 | 17 |
GO:19033114 | Colorectum | FAP | regulation of mRNA metabolic process | 97/2622 | 288/18723 | 1.35e-17 | 4.13e-14 | 97 |
GO:00098964 | Colorectum | FAP | positive regulation of catabolic process | 126/2622 | 492/18723 | 3.76e-12 | 2.56e-09 | 126 |
GO:00506844 | Colorectum | FAP | regulation of mRNA processing | 51/2622 | 137/18723 | 9.70e-12 | 4.96e-09 | 51 |
GO:00434844 | Colorectum | FAP | regulation of RNA splicing | 53/2622 | 148/18723 | 2.16e-11 | 1.02e-08 | 53 |
GO:00480244 | Colorectum | FAP | regulation of mRNA splicing, via spliceosome | 41/2622 | 101/18723 | 4.36e-11 | 1.78e-08 | 41 |
GO:00313314 | Colorectum | FAP | positive regulation of cellular catabolic process | 110/2622 | 427/18723 | 6.09e-11 | 2.19e-08 | 110 |
GO:00083804 | Colorectum | FAP | RNA splicing | 108/2622 | 434/18723 | 7.90e-10 | 1.86e-07 | 108 |
GO:00610134 | Colorectum | FAP | regulation of mRNA catabolic process | 54/2622 | 166/18723 | 8.64e-10 | 1.96e-07 | 54 |
GO:00064024 | Colorectum | FAP | mRNA catabolic process | 68/2622 | 232/18723 | 9.87e-10 | 2.16e-07 | 68 |
GO:00064014 | Colorectum | FAP | RNA catabolic process | 77/2622 | 278/18723 | 1.42e-09 | 2.77e-07 | 77 |
GO:00434874 | Colorectum | FAP | regulation of RNA stability | 53/2622 | 170/18723 | 6.61e-09 | 1.00e-06 | 53 |
GO:00003754 | Colorectum | FAP | RNA splicing, via transesterification reactions | 84/2622 | 324/18723 | 8.06e-09 | 1.10e-06 | 84 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ELF1 | SNV | Missense_Mutation | | c.151N>G | p.Leu51Val | p.L51V | P32519 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
ELF1 | SNV | Missense_Mutation | | c.1248N>C | p.Gln416His | p.Q416H | P32519 | protein_coding | tolerated(0.36) | possibly_damaging(0.759) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
ELF1 | SNV | Missense_Mutation | | c.133N>G | p.Leu45Val | p.L45V | P32519 | protein_coding | deleterious(0.02) | possibly_damaging(0.678) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ELF1 | SNV | Missense_Mutation | novel | c.740N>T | p.Ser247Phe | p.S247F | P32519 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
ELF1 | SNV | Missense_Mutation | | c.1685N>G | p.Thr562Arg | p.T562R | P32519 | protein_coding | deleterious(0.04) | benign(0.136) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ELF1 | insertion | Frame_Shift_Ins | novel | c.101_102insT | p.Ile35AsnfsTer9 | p.I35Nfs*9 | P32519 | protein_coding | | | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ELF1 | SNV | Missense_Mutation | rs766946264 | c.1472C>T | p.Ala491Val | p.A491V | P32519 | protein_coding | tolerated(0.34) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ELF1 | SNV | Missense_Mutation | rs747465409 | c.371T>C | p.Ile124Thr | p.I124T | P32519 | protein_coding | tolerated(0.05) | benign(0.165) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ELF1 | SNV | Missense_Mutation | | c.1397N>G | p.Phe466Cys | p.F466C | P32519 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ELF1 | SNV | Missense_Mutation | novel | c.700G>A | p.Glu234Lys | p.E234K | P32519 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |